Capricor Therapeutics Faces Class Action Over Securities Fraud

Author: Evelyn Baker Updated: 08-21-2025 10:42 AM

Capricor Therapeutics and Recent Developments

Capricor Therapeutics, Inc. is gaining attention as investors become aware of potential legal issues related to its securities. A national law firm is currently spearheading a class action lawsuit against the company for alleged violations of securities laws. These serious allegations revolve around misleading statements made by the company regarding their drug candidate, deramiocel.

Allegations of Misleading Information

According to the lawsuit, Capricor Therapeutics made claims that were not fully supported by the realities of the situation. The company has been promoting its progress toward FDA approval for deramiocel, highlighting a mid-cycle review that appeared promising. However, the lawsuit accuses Capricor of concealing crucial adverse data from a significant Phase 2 clinical trial known as HOPE-2.

Understanding Class Period and Participation

The class period during which these alleged securities violations occurred includes all transactions from a specified start to end date. Investors who purchased shares within this timeframe are encouraged to assess their legal options. Interested individuals can contact the representing law firm to explore joining the class action and seeking potential recovery for their investment losses.

Impact on Investors

For shareholders affected by these developments, the implications of the lawsuit are significant. The lawsuit reflects the complexities of investing in biotech firms where the outcomes of drug trials can heavily influence stock prices. The allegations suggest that when the true nature of the drug's trial results became public knowledge, many investors suffered financial damages as a result of these previous misrepresentations.

Steps for Affected Investors

If you are an investor in Capricor Therapeutics who feels they may have been misled by the company's communications, it's essential to act promptly. Engaging with legal representation can provide insight into your rights. It's worth discussing your options with professionals who specialize in shareholder rights litigation.

Contact Information

Investors considering their options can reach out to Brian Schall at The Schall Law Firm located at 2049 Century Park East, Suite 2460. You can also contact them at 310-301-3335 for a free consultation about your rights. Additionally, further details are available on their website.

The Role of The Schall Law Firm

The Schall Law Firm is known for advocating for shareholders and navigating the complexities of securities litigation. As specialists in this niche, their experience can be a guiding factor for investors seeking justice and possible recovery from investment losses.

Frequently Asked Questions

What is the nature of the lawsuit against Capricor Therapeutics?

The lawsuit claims Capricor made false statements regarding the efficacy and regulatory progress of its drug candidate, deramiocel, which misled investors.

Who can participate in the class action?

Investors who purchased Capricor's securities within a designated time frame could be eligible to join the class action lawsuit.

How can I join the class action?

Individuals interested in participating should contact the law firm representing the class action to discuss their eligibility and options for recovery.

What are the possible outcomes of the lawsuit?

Outcomes may include financial compensation for affected investors, depending on the court’s rulings and settlement negotiations.

What should I do if I sold my shares?

Even if shares were sold during the class period, it may still be worthwhile to consult with legal counsel. Analyze whether you might still have a claim.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.